1. Prospective Validation of Glial Fibrillary Acidic Protein, d‐Dimer, and Clinical Scales for Acute Large‐Vessel Occlusion Ischemic Stroke Detection
- Author
-
Yasir Durrani, Jakob V. E. Gerstl, Danielle Murphy, Ashley Harris, Imane Saali, Toby Gropen, Shashank Shekhar, Ari D. Kappel, Nirav J. Patel, Rose Du, Rodolfo E. Alcedo Guardia, Juan C. Vicenty‐Padilla, Adam A. Dmytriw, Vitor Mendes Pereira, Saef Izzy, Allauddin Khan, Mohammed A. Aziz‐Sultan, David S. Liebeskind, Jason M. Davies, Adnan H. Siddiqui, Edoardo Gaude, and Joshua D. Bernstock
- Subjects
biomarkers ,glial fibrillary acidic protein (GFAP) ,intracerebral hemorrhage (ICH) ,large‐vessel occlusion (LVO) ,stroke ,thrombectomy (EVT) ,Neurology. Diseases of the nervous system ,RC346-429 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background Large‐vessel occlusion (LVO) ischemic stroke is responsible for significant morbidity and mortality. We have previously described a novel tool for acute LVO detection that combines blood‐based biomarkers (glial fibrillary acidic protein and d‐dimer) with stroke severity scales to achieve high accuracy. Accordingly, the present study sought to prospectively validate cutoff values that we had previously established for biomarkers and scales. Methods The TIME (Testing for Identification Markers of Stroke) trial was designed as a prospective observational diagnostic accuracy study. All ambulance‐identified stroke code activations
- Published
- 2024
- Full Text
- View/download PDF